Maplight Therapeutics (NASDAQ:MPLT) Director Sells $119,990.64 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 6,622 shares of Maplight Therapeutics stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $18.12, for a total transaction of $119,990.64. Following the completion of the transaction, the director directly owned 351,611 shares in the company, valued at approximately $6,371,191.32. The trade was a 1.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Maplight Therapeutics Price Performance

NASDAQ:MPLT opened at $17.22 on Friday. The stock has a market capitalization of $781.27 million and a PE ratio of -0.46. Maplight Therapeutics, Inc. has a 52 week low of $12.24 and a 52 week high of $21.55. The company’s 50 day moving average price is $18.15.

Maplight Therapeutics (NASDAQ:MPLT) last released its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Hedge Funds Weigh In On Maplight Therapeutics

A number of institutional investors have recently bought and sold shares of MPLT. Strs Ohio purchased a new stake in shares of Maplight Therapeutics in the 4th quarter valued at $53,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Maplight Therapeutics in the fourth quarter valued at $70,000. New York State Common Retirement Fund acquired a new stake in Maplight Therapeutics during the 4th quarter worth about $93,000. MetLife Investment Management LLC purchased a new position in shares of Maplight Therapeutics during the 4th quarter valued at about $172,000. Finally, Walleye Capital LLC acquired a new position in shares of Maplight Therapeutics in the 4th quarter valued at about $205,000.

Analyst Ratings Changes

Several equities research analysts have weighed in on MPLT shares. Weiss Ratings assumed coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating for the company. Wall Street Zen upgraded shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Stifel Nicolaus initiated coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $28.00 price target on the stock. Leerink Partners assumed coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued an “outperform” rating and a $30.00 price target for the company. Finally, Jefferies Financial Group began coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $32.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $31.00.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.